Daiichi Sankyo Company Limited (DSKYF.PK) News Headlines

▮ More

Date

Headline

1/20/2021 2:30:49 AM AstraZeneca And Daiichi Sankyo's Enhertu Approved In EU For Breast Cancer

1/18/2021 3:00:48 AM AstraZeneca, Daiichi Sankyo: Enhertu Gets US Approval For HER2-positive Advanced Gastric Cancer

1/18/2021 2:03:37 AM AstraZeneca And Daiichi Sankyo Announce Enhertu Approved In The US For Gastric Cancer

12/16/2020 4:35:03 AM Daiichi Sankyo, Esperion Report Swissmedic Approval For NILEMDO & NUSTENDI

12/14/2020 8:48:52 AM Daiichi Sankyo And AstraZeneca Announce Initiation Of TROPION-Lung01

12/10/2020 8:02:42 AM AstraZeneca, Daiichi Sankyo: ENHERTU Demonstrated Durable Responses In Phase II Trial

7/27/2020 2:22:11 AM AstraZeneca In Deal To Develop, Commercialise Daiichi Sankyo's DS-1062 For Upfront Payment Of $1 Bln

7/27/2020 2:02:47 AM AstraZeneca And Daiichi Sankyo Enter Collaboration To Develop DS-1062

5/29/2020 8:41:39 AM AstraZeneca : Phase II DESTINY-CRC01 Trial Shows Clinically Meaningful Activity In Colorectal Cancer

5/22/2020 2:49:55 AM AstraZeneca: FDA Grants Orphan Drug Designation To Enhertu For Gastric Cancer

5/18/2020 2:22:16 AM Enhertu Granted BTD In US For HER2-mutant Metastatic Non-small Cell Lung Cancer

5/11/2020 3:10:44 AM AstraZeneca: FDA Grants Second Breakthrough Therapy Designation To Enhertu

5/7/2020 8:15:20 AM Daiichi Sankyo Submits SNDA To Japan's MHLW For Trastuzumab Deruxtecan

1/27/2020 2:35:54 AM AstraZeneca: Brilinta, Enhertu Met Primary Endpoint In Respective Trials

1/27/2020 2:07:43 AM AstraZeneca: Phase II DESTINY-Gastric01 Trial Of Enhertu Vs Chemotherapy Met Primary Endpoint

12/23/2019 2:29:18 AM AstraZeneca: US Approves Enhertu, China Approves Triple-combination For COPD

11/5/2019 12:19:44 AM Seattle Genetics Responds To Daiichi Sankyo's Declaratory Judgment Complaint

10/31/2019 5:50:23 AM Daiichi Sankyo H1 Profit Climbs; Lifts FY19 Outlook

10/31/2019 4:21:15 AM Daiichi Sankyo H1 Revenue Up 32.7% To 479.6 Bln Yen

10/17/2019 2:50:03 AM AstraZeneca: FDA Grants Priority Review For Trastuzumab Deruxtecan